Equities research analysts have released updated earnings per share (EPS) estimates and maintained ratings for several companies ahead of February 9th. HC Wainwright reaffirmed its buy rating on Aardvark Therapeutics (NASDAQ: AARD) with a target price of $40.00. Similarly, Cantor Fitzgerald reiterated its overweight rating on Affirm (NASDAQ: AFRM), setting a target price of $85.00.
Other companies covered in the update include BVS, CNC, DAVE, DBD, DEVO, ENTX, ERIC, and ESLA, with analysts providing revised EPS forecasts and price targets based on recent financial performance and market conditions.
**Why this matters**
Updated EPS estimates and analyst ratings can influence investor sentiment and trading decisions. These revisions reflect analysts’ latest views on company performance and growth prospects, which can impact stock prices and market dynamics ahead of earnings announcements.
Source: NewsData